Increase in primary drug resistance of Mycobacterium tuberculosis in younger birth cohorts in France

Journal of Infection

Volumn 64, Issue 6, 2012, Pages 589-595

  Meyssonnier, Vanina ^a   Veziris, Nicolas ^a,b   Bastian, Sylvaine ^a,b   Texier Maugein, Jeanne ^c   Jarlier, Vincent ^a,b   Robert, Jérôme ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

Isoniazid; Mycobacterium tuberculosis; Primary resistance; Rifampicin; Streptomycin

Indexed keywords

ISONIAZID; RIFAMPICIN; STREPTOMYCIN;

AGE; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BIRTH; COHORT ANALYSIS; FEMALE; FRANCE; GEOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MYCOBACTERIUM TUBERCULOSIS; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS; TUBERCULOSIS; UNIVERSITY HOSPITAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, BACTERIAL; FEMALE; FRANCE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; ISONIAZID; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84860627672     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2012.01.013     Document Type: Article

References (23)

1. Guidelines for surveillance of drug resistance in tuberculosis 2009, WHO, WHO/HTM/TB/2009.422. 4th ed.
2. Tuberculosis programs. Review, planning, technical support. A manual of methods and procedures 1998, IUATLD.
3. American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors JTswebtCotI Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000, 161(4 Pt 1):1376-1395.
4. Khue P.M., Truffot-Pernot C., Texier-Maugein J., Jarlier V., Robert J. A 10-year prospective surveillance of Mycobacterium tuberculosis drug resistance in France - 1995-2004. Eur Respir J 2007, 30:937-944.
5. WHO/IUATLD Antituberculosis drug resistance in the world 2008, Report No 4. The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance - 2002-2007 - WHO/HTM/TB/2008.394, World Health Organization, Geneva.
6. Global tuberculosis control: A short update to the 2009 report 2009, WHO, [accessed 2008/2002/2010]. http://www.who.int/tb/publications/global_report/2009/update/en/index.html.
7. Vinnard V., Winston C.A., Wileyto E.P., MacGregor R.R., Bisson G.P. Isoniazid-resistant tuberculous meningitis, United States, 1993-2005. Emerg Infect Dis 2011, 17:539-542.
8. Kruijshaar M.E., Watson J.M., Drobniewski F., Anderson C., Brown T.J., Magee J.G., et al. Increasing antituberculosis drug resistance in the United Kingdom: analysis of National Surveillance Data. BMJ 2008, 336:1231-1234.
9. Heifets L. Susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J Med Microbiol 2002, 51:11-12.
10. Hoopes A.J., Kammerer J.S., Harrington T.A., Ijaz K., Armstrong L.R. Isoniazid-monoresistant tuberculosis in the United States, 1993 to 2003. Arch Intern Med 2008, 168:1984-1992.
11. Forssbohm M., Loddenkemper R., Rieder H.L. Isoniazid resistance among tuberculosis patients by birth cohort in Germany. Int J Tuberc Lung Dis 2003, 7:973-979.
12. Antoine D., Che D. Les cas de tuberculose maladie déclarés en France en 2007. Bull Epidemiol Hebdo 2009, 12-13:106-109.
13. Société de Pneumologie de Langue Française Recommandations de la Société de Pneumologie de Langue Française sur la prise en charge de la tuberculose en France. Rev Mal Respir 2004, 21:414-420. Conférence d'experts - texte court.
14. American Thoracic Society, Centers for Disease Control, Infectious Diseases Society of America Treatment of tuberculosis. MMWR 2003, 52(RR-11).
15. Cattamanchi A., Dantes R.B., Metcalfe J.Z., Jarlsberg L.G., Grinsdale J., Kawamura L.M., et al. Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis. Clin Infect Dis 2009, 48:179-185.
16. Balcells M.E., Thomas S.L., Godfrey-Faussett P., Grant A.D. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis 2006, 12:744-751.
17. EuroTB (InVS/KNCV) and the national coordinators for tuberculosis surveillance in the WHO European region. Surveillance of tuberculosis in Europe. Report on tuberculosis case notified in 2006, Saint Maurice; 2008 [08/02/2010].
18. Ridzon R., Whitney C.G., McKenna M.T., Taylor J.P., Ashkar S.H., Nitta A.T., et al. Risk factors for rifampin mono-resistant tuberculosis. Am J Respir Crit Care Med 1998, 157:1881-1884.
19. Robert J., Trystram D., Truffot-Pernot C., Jarlier V. Multidrug-resistant tuberculosis: eight years of surveillance in France. Eur Respir J 2003, 22:833-837.
20. Manissero D., Hollo V., Huitric E., Ködmön C., Amato-Gauci A. Analysis of tuberculosis treatment outcomes in the European Union and European Economic Area: efforts needed towards optimal case management and control. Euro Surveill 2010, 15(11). Available from:, pii=19514. http://www.eurosurveillance.org/ViewArticle.aspx%3FArticleId%3D19514.
21. Cazein F., Pillonel J., Le Strat Y., Lot F., Pinget R., David D., et al. Surveillance de l'infection à VIH-sida en France, 2007. Bull Epid Hebdo 2008, 45-46:434-443.
22. Antoine D., Che D. Treatment outcome of tuberculosis cases notified in France in 2008. Bull Epid Hebdo 2011, 32:345-348.
23. Dautzenberg B., Frechet-Jachym M., Maffre J.P., Cardot E., Grignet J.P. When should standard treatment not be applied for the tuberculosis patient?. Rev Mal Respir 2004, 21:S75-S97.